Isofol Medical Management
Management criteria checks 0/4
Isofol Medical's CEO is Petter Lindqvist, appointed in Jan 2024, has a tenure of less than a year. directly owns 0.04% of the company’s shares, worth €17.28K. The average tenure of the management team and the board of directors is 0.8 years and 0.8 years respectively.
Key information
Petter Lindqvist
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.04% |
| Management average tenure | less than a year |
| Board average tenure | less than a year |
Recent management updates
Recent updates
CEO
Petter Lindqvist
less than a year
Tenure
Mr. Petter Segelman Lindqvist serves as Chief Executive Officer of Isofol Medical AB (publ) since January 09, 2024. He is Chief Executive Officer of Hamlet BioPharma AB (publ) (formerly known as Hamlet Pha...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | less than a year | no data | 0.040% SEK 17.3k | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
0.8yrs
Average Tenure
Experienced Management: 5IU's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Chairman | less than a year | SEK 996.00k | 0.40% SEK 169.3k | |
| Independent Director | less than a year | no data | 0.0019% SEK 820.3 | |
| Independent Director | less than a year | SEK 29.00k | 0.25% SEK 107.8k | |
| Independent Director | less than a year | SEK 271.00k | no data | |
| Independent Director | less than a year | no data | no data |
0.8yrs
Average Tenure
77.5yo
Average Age
Experienced Board: 5IU's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.